These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17852832)

  • 1. Decreased serum endoglin level in patients with amyotrophic lateral sclerosis: a preliminary report.
    Iłzecka J
    Scand J Clin Lab Invest; 2008; 68(4):348-51. PubMed ID: 17852832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased serum-soluble TRAIL levels in patients with amyotrophic lateral sclerosis.
    Iłzecka J
    Acta Neurol Scand; 2008 May; 117(5):343-6. PubMed ID: 17995989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum soluble OX40 in patients with amyotrophic lateral sclerosis.
    Iłzecka J
    Acta Clin Croat; 2012 Mar; 51(1):3-7. PubMed ID: 22919996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granzymes A and B levels in serum of patients with amyotrophic lateral sclerosis.
    Iłżecka J
    Clin Biochem; 2011 Jun; 44(8-9):650-3. PubMed ID: 21349256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased cerebrospinal fluid cytochrome c levels in patients with amyotrophic lateral sclerosis.
    Iłzecka J
    Scand J Clin Lab Invest; 2007; 67(3):264-9. PubMed ID: 17454840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis.
    Iłzecka J
    Acta Neurol Scand; 2006 Sep; 114(3):205-9. PubMed ID: 16911350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMMPRIN levels in serum of patients with amyotrophic lateral sclerosis.
    Iłżecka J
    Acta Neurol Scand; 2011 Dec; 124(6):424-8. PubMed ID: 21554254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis.
    Iłzecka J
    Acta Neurol Scand; 2009 Aug; 120(2):119-22. PubMed ID: 19053950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased serum CNTF level in patients with amyotrophic lateral sclerosis.
    Iłzecka J
    Eur Cytokine Netw; 2003; 14(3):192-4. PubMed ID: 14656696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin.
    Wipff J; Avouac J; Borderie D; Zerkak D; Lemarechal H; Kahan A; Boileau C; Allanore Y
    Rheumatology (Oxford); 2008 Jul; 47(7):972-5. PubMed ID: 18477643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1beta converting enzyme/Caspase-1 (ICE/Caspase-1) and soluble APO-1/Fas/CD 95 receptor in amyotrophic lateral sclerosis patients.
    Iłzecka J; Stelmasiak Z; Dobosz B
    Acta Neurol Scand; 2001 Apr; 103(4):255-8. PubMed ID: 11328198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis.
    Lin CY; Pfluger CM; Henderson RD; McCombe PA
    J Neuroimmunol; 2012 Aug; 249(1-2):93-5. PubMed ID: 22633272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS).
    Fang L; Huber-Abel F; Teuchert M; Hendrich C; Dorst J; Schattauer D; Zettlmeissel H; Wlaschek M; Scharffetter-Kochanek K; Tumani H; Ludolph AC; Brettschneider J
    J Neurol Sci; 2009 Oct; 285(1-2):62-6. PubMed ID: 19523650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma amino acids concentration in amyotrophic lateral sclerosis patients.
    Iłzecka J; Stelmasiak Z; Solski J; Wawrzycki S; Szpetnar M
    Amino Acids; 2003 Jul; 25(1):69-73. PubMed ID: 12836061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients.
    Iłzecka J
    Acta Neurol Scand; 2003 Aug; 108(2):125-9. PubMed ID: 12859290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum caspase-9 levels are increased in patients with amyotrophic lateral sclerosis.
    Iłżecka J
    Neurol Sci; 2012 Aug; 33(4):825-9. PubMed ID: 22048794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased cerebrospinal fluid cGMP levels in patients with amyotrophic lateral sclerosis.
    Iłecka J
    J Neural Transm (Vienna); 2004 Feb; 111(2):167-72. PubMed ID: 14767719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis.
    Iłzecka J
    Clin Neurol Neurosurg; 2004 Sep; 106(4):289-93. PubMed ID: 15297002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis.
    Iłzecka J; Kocki T; Stelmasiak Z; Turski WA
    Acta Neurol Scand; 2003 Jun; 107(6):412-8. PubMed ID: 12757473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.